Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/22/2024 | $8.00 | Buy | Rodman & Renshaw |
| 11/16/2023 | $2.00 → $4.00 | Neutral → Outperform | Wedbush |
| 1/4/2022 | $4.00 | Neutral → Buy | Roth Capital |
| 1/4/2022 | Neutral → Buy | ROTH Capital | |
| 11/10/2021 | $5.00 → $7.00 | Neutral → Buy | Mizuho |
| 6/28/2021 | Sell → Buy | Citigroup | |
| 6/28/2021 | $6.00 | Sell → Buy | Citigroup |
8-K - Unity Biotechnology, Inc. (0001463361) (Filer)
10-Q - Unity Biotechnology, Inc. (0001463361) (Filer)
8-K - Unity Biotechnology, Inc. (0001463361) (Filer)
A single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in Best Corrected Visual Acuity (BCVA) of +6.2 ETDRS letters from baseline at 48 weeks Approximately 53% of UBX1325-treated patients did not require any additional injections through 48 weeks Retinal structure, as measured by central subfield thickness (CST), was maintained in UBX1325-treated patients throughout the duration of the study UBX1325 had a favorable safety and tolerability profile with no evidence of intraocular inflammation UNITY to host investor call with retinal expert Robert B. Bhisitkul, M.D., Ph.D., today, April 24 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., April
UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm UBX1325 maintained visual acuity in patients with ongoing active disease through 24 weeks with less than one letter mean decrease from baseline 52% of UBX1325-treated patients did not require anti-VEGF treatment through 24 weeks Company to share 48-week BEHOLD DME data in April and intends to initiate Phase 2b study in DME in second half of 2023 UNITY to host investor call today, March 27, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company d
A single injection of UBX1325 led to a statistically significant and clinically relevant improvement in Best Corrected Visual Acuity (BCVA) of 7.6 ETDRS letters at 24 weeks compared to sham treatment UBX1325 maintained stabilization of retinal structure, as measured by central subfield thickness (CST) at 24 weeks, as compared to worsening from baseline in sham-treated patients The proportion of rescue-free patients in the UBX1325-treated arm was 59.4% at 6 months after a single injection, as compared to only 37.5% in the sham-treated arm UNITY to host investor call with retinal expert Arshad M. Khanani, M.D., M.A., FASRS, today, November 1, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., No
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that on January 6, 2025, the Compensation Committee of the Board of Directors (the "Board") granted a stock-based award to a new employee, Federico Grossi, UNITY's Chief Medical Officer, covering options to purchase 150,000 shares of UNITY common stock. The stock-based award was granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material indu
SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today strengthened the executive leadership team with the appointment of Federico Grossi, M.D., Ph.D., as chief medical officer. Dr. Grossi brings a wealth of experience in clinical development and regulatory strategy in ophthalmology and other indications, most recently having led the development of SYFOVRE for geographic atrophy as chief medical officer at Apellis Pharmaceuticals. "Dr. Grossi's extensive experience in clinical strategy and a successful track record of advancing novel ophthalmolo
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2024. "As recently discussed on our Ophthalmology Day for investors and analysts, diabetic macular edema represents a large underserved market due to inadequate response to anti-VEGF standard of care, continued vision loss over time despite treatment, and high treatment burden leading to discontinuation," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "We believe that UBX1325 (foselutoclax) with i
Rodman & Renshaw initiated coverage of Unity Biotechnology with a rating of Buy and set a new price target of $8.00
Wedbush upgraded Unity Biotechnology from Neutral to Outperform and set a new price target of $4.00 from $2.00 previously
Roth Capital upgraded Unity Biotechnology from Neutral to Buy and set a new price target of $4.00
4 - Unity Biotechnology, Inc. (0001463361) (Issuer)
3 - Unity Biotechnology, Inc. (0001463361) (Issuer)
4 - Unity Biotechnology, Inc. (0001463361) (Issuer)
SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)
SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)
SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)
SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today strengthened the executive leadership team with the appointment of Federico Grossi, M.D., Ph.D., as chief medical officer. Dr. Grossi brings a wealth of experience in clinical development and regulatory strategy in ophthalmology and other indications, most recently having led the development of SYFOVRE for geographic atrophy as chief medical officer at Apellis Pharmaceuticals. "Dr. Grossi's extensive experience in clinical strategy and a successful track record of advancing novel ophthalmolo
SAN FRANCISCO, July 22, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Alicia Tozier, MBA, as chief strategy officer. In this new role, she will develop and implement the company's corporate and product strategies. "Alicia's impressive experience in ophthalmology product planning, commercial strategy, and scaling cross-functional teams will be instrumental in fortifying our strategies and capitalizing on the significant opportunity of UBX1325 to transform the treatment landscape for diabetic macular edema (DME)," said Anirvan Ghosh, Ph.
SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Michael Samar, current chief financial officer at Assembly Bio, has been appointed to the Company's board of directors as its chair of the audit committee and a member of its compensation committee. "We're thrilled to add Michael to UNITY's board of directors. With his strong background in biotech finance and operations, combined with an energetic fresh perspective and track record of execution, Michael's strategic perspective will be vital as we focus on executing on our UBX1325